Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.
-
Chen X, Xie Q, Nath SJ, Tang M, Ma H, G?nes Y?, Sharma T, Liu H, Cui M, Du A, Lu M, Liu SY, Wassamon B, Xu M, Wu JY, Su Q, Fitzgibbons TP, Liu J, Wan F, Kumanan V, He R, Ma Y, Yang J, Gray-Edwards HL, Gallagher TL, Tai PWL, Gao G, Xie J. Long-term comparative analysis of AAV9-mediated gene replacement therapies for spinal muscular atrophy in mice. Nat Commun. 2026 May 23; 17(1).
-
Shah J, Makwana B, Panchal K, Patel V, Patel T, Khadke S, Verma A, Vivekanandan S, Kong Y, Upadhyay J, Dani SS, Ramsey KM, Ganatra S, Ramsey DJ. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy. Am J Ophthalmol. 2026 Aug; 288:131-142.
-
Golonka RM, Intravaia LE, Shaqra AM, Li Q, Chen Y, Humphries F, Kurt-Yilmaz N, Fitzgerald KA, Schiffer CA, Wang Y, Cavacini LA. Engineered IgA-Fc fusion protein with bioactive nanobody neutralizes SARS-CoV-2 variants with mucosal delivery potential. J Biol Chem. 2026 Mar; 302(3):111210.
-
Naeem A, Bolaji O, Kidess GG, Fahed J, Jahan S, Basit J, Khan MH, Mangeshkar S, Sorci S, Kassis-George H, Dani S, Alraies MC. Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up. Int J Cardiol. 2026 Mar 15; 447:134150.
-
Almeida GG, Pinto JA, Pinto PM, da Silva LB, Andrade LAF, Valiate BVS, Zini N, Bagno FF, Rivelli GG, Louren?o KL, Souza JPC, Gomes IP, de Castro NS, Maia ALC, de Carvalho AF, Alves JC, de Castro JT, Li G, da Rocha Fernandes G, Alves PA, Diniz RC, Daher AB, de Souza RP, Teixeira SMR, Fernandes APSM, Gazzinelli RT, da Costa Santiago H. Safety and immunogenicity of SpiN-Tec, a T-cell based RBD-Nucleocapsid chimeric vaccine for COVID-19. Vaccine. 2025 Oct 03; 64:127756.
-
Abdulelah M, Ezenna C, Jenil-Franco A, Jamouss KT, Krishna MM, Joseph M, Chi KY, Dahhan T. Clinical outcomes and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized controlled trials. Vascul Pharmacol. 2025 Sep; 160:107520.
-
Wu QC, Lee J, Swaminathan A, Winward A, Hwang Y, Socolovsky M, Way JC, Klein AM. Linker minimization and characterization of Fc-fused interleukin-17A for increased in vivo half-life. Protein Eng Des Sel. 2025 Jan 10; 38.
-
Servais L, Day JW, De Vivo DC, Kirschner J, Mercuri E, Muntoni F, Proud CM, Shieh PB, Tizzano EF, Quijano-Roy S, Desguerre I, Saito K, Faulkner E, Benguerba KM, Raju D, LaMarca N, Sun R, Anderson FA, Finkel RS. Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry. J Neuromuscul Dis. 2024; 11(2):425-442.
-
Archambault SD, Nichols MM, McCullum JC, Zhang Y, Steinberger EE, Ramsey DJ. Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration. Indian J Ophthalmol. 2024 01 01; 72(Suppl 1):S101-S105.
-
Harwood OE, Balgeman AJ, Weaver AJ, Ellis-Connell AL, Weiler AM, Erickson KN, Matschke LM, Golfinos AE, Vezys V, Skinner PJ, Safrit JT, Edlefsen PT, Reynolds MR, Friedrich TC, O'Connor SL. Transient T Cell Expansion, Activation, and Proliferation in Therapeutically Vaccinated Simian Immunodeficiency Virus-Positive Macaques Treated with N-803. J Virol. 2022 12 14; 96(23):e0142422.